Equities

Burzynski Research Institute Inc

BZYR:PKC

Burzynski Research Institute Inc

Actions
  • Price (USD)0.0443
  • Today's Change0.00 / 0.00%
  • Shares traded1.00k
  • 1 Year change-47.85%
  • Beta1.0083
Data delayed at least 15 minutes, as of Jun 26 2024 17:16 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and are reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. The Company conducted all the Phase II clinical trials for the treatment of a variety of cancers using the combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons; however, a few trials use oral formulations. The Company has not generated any operating revenue since its inception. The Company's clinical trials are conducted at the Burzynski Clinic.

  • Revenue in USD (TTM)0.00
  • Net income in USD-1.34m
  • Incorporated1980
  • Employees2.00
  • Location
    Burzynski Research Institute Inc12000 Richmond AveHOUSTON 77082United StatesUSA
  • Phone+1 (713) 335-5697
  • Fax+1 (713) 935-0649
  • Websitehttp://burzynskiresearch.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pasithea Therapeutics Corp0.00-16.10m5.40m8.00--0.2718-----14.03-14.170.0019.060.00----0.00-49.97---53.80--------------0.00-------32.23------
BioCardia Inc468.00k-10.34m5.44m16.00------11.63-7.04-7.040.3132-1.270.0954--4.4429,250.00-210.81-107.34-1,190.90-154.17-----2,208.76-1,779.24---------64.72-5.262.82---28.89--
Tron Pharmaceuticals Inc1.01m-549.47k5.50m50.00------5.45-0.0034-0.00340.0062-0.0508------20,191.00--------60.28---110.51--0.0417-433.32----0.3272---39.70------
Fresh Tracks Therapeutics Inc8.01m-5.69m5.55m4.00--0.5591--0.6934-1.38-1.381.491.660.7326----2,001,500.00-52.10-89.76-66.50-115.24-----71.12-442.61---1,272.000.00--15.3137.6273.02------
Hepion Pharmaceuticals Inc0.00-38.52m5.58m22.00--0.9582-----9.49-9.490.001.370.00----0.00-117.64-61.43-145.05-68.82-----------3,240.310.00-------7.92------
TFF Pharmaceuticals Inc885.71k-19.93m5.61m19.00--0.8596--6.33-10.20-10.200.43712.110.0647--3.7246,616.32-145.46-79.57-181.57-83.41-----2,249.83-8,687.66----0.00--48.01--33.13------
HST Global Inc0.00-141.11k5.72m1.00---------0.0269-0.02690.00-0.11930.00-------29,397.92-5,836.01---------------24.24---------0.7858------
Intelligent Bio Solutions Inc2.83m-10.03m5.74m17.00--0.4816--2.03-64.14-64.144.603.820.20412.697.77166,299.40-72.67-80.65-107.67-224.8423.33---356.09-948.541.87--0.0451--187.51367.97-28.00------
Transcode Therapeutics Inc0.00-17.06m5.75m10.00--1.10-----206.36-206.360.000.78930.00----0.00-264.82-133.14-721.90-181.26-----------148.050.00-------5.59------
Xenetic Biosciences Inc2.44m-4.47m5.77m4.00--0.6648--2.36-2.92-2.921.595.630.2116----611,240.00-38.71-48.91-41.54-52.82-----182.95-682.42----0.00--48.80--36.90------
CeCors Inc-100.00bn-100.00bn5.81m6.00---------------0.0163------------------------------------22.70------
Burzynski Research Institute Inc0.00-1.34m5.83m2.00---------0.0102-0.01020.00-0.00020.00-------62,992.45-15,304.89-------------------------45.74------
NuCana PLC (ADR)0.00-33.94m5.85m25.00--0.4868-----303.31-303.310.005.680.00----0.00-72.34-41.01-125.17-48.07------------0.0324------13.71---21.70--
Ainos Inc93.68k-14.56m5.91m46.00--0.2547--63.06-3.27-3.270.02063.690.00280.81331.622,036.52-43.83-36.36-48.64-58.33-222.1136.82-15,547.49-813.630.2847-75.230.2003---96.539.461.69--66.44--
Cyclerion Therapeutics Inc0.00-10.95m6.11m1.00--0.568-----4.380.29040.003.970.00----0.00-95.95-72.70-158.12-86.96-------2,565.62----0.00---100.00--30.98------
Tenax Therapeutics Inc0.00-10.10m6.23m5.00--0.501-----24.52-24.520.006.350.00----0.00-67.96-199.16-75.66-285.64-----------105.120.0322------30.21------
Data as of Jun 26 2024. Currency figures normalised to Burzynski Research Institute Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.